J INTERN MED:早期抗病毒治疗有助于缓解新型冠状病毒病感染者的严重程度并改善预后

2020-03-28 MedSci原创 MedSci原创

老年人和有基础疾病的患者更有可能经历严重的COVID‐19。建议及时抗病毒治疗,以延缓病情进展,改善患者预后。

目前,严重急性呼吸系统综合征冠状病毒2(SARS‐CoV‐2)感染患者的严重程度一直是人们关注的焦点。近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,研究人员旨在评估SARS‐CoV‐2患者的严重程度和预后相关因素。

研究人员回顾性地调查了2020年1月20日至2月20日期间确诊的280例新型冠状病毒疾病(COVID‐19)感染者的临床、影像学和实验室结果特征。

轻症患者中位年龄为37.55岁,重症患者中位年龄为63.04岁。重症组中65岁以上患者的比例明显高于轻症组(59.04% vs. 10.15%,P<0.05)。85.54%的重症患者有糖尿病或心血管疾病,比例明显高于轻症组(51.81% vs 7.11%,P=0.025;33.73% vs 3.05%,P=0.042)。轻症组患者较早开始抗病毒治疗(1.19±0.45天 vs. 重度组患者为2.65±1.06天,P<0.001)。该研究表明合并症、从发病到抗病毒的时间、年龄超过65岁是COVID‐19病情进展的三个主要危险因素,而合并症和从发病到抗病毒的时间是COVID‐19患者康复的两个主要危险因素。

由此可见,老年人和有基础疾病的患者更有可能经历严重的COVID‐19。建议及时抗病毒治疗,以延缓病情进展,改善患者预后。

原始出处:

Jian Wu,et al.Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19).J INTERN MED. 2020.https://onlinelibrary.wiley.com/doi/10.1111/joim.13063

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056093, encodeId=67e5205609398, content=<a href='/topic/show?id=4d3058191e5' target=_blank style='color:#2F92EE;'>#新型冠状病毒病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58191, encryptionId=4d3058191e5, topicName=新型冠状病毒病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Jul 29 02:33:02 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292510, encodeId=2b2512925107f, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292882, encodeId=33d8129288256, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610394, encodeId=7f1416103948c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056093, encodeId=67e5205609398, content=<a href='/topic/show?id=4d3058191e5' target=_blank style='color:#2F92EE;'>#新型冠状病毒病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58191, encryptionId=4d3058191e5, topicName=新型冠状病毒病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Jul 29 02:33:02 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292510, encodeId=2b2512925107f, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292882, encodeId=33d8129288256, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610394, encodeId=7f1416103948c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-03-30 yahu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056093, encodeId=67e5205609398, content=<a href='/topic/show?id=4d3058191e5' target=_blank style='color:#2F92EE;'>#新型冠状病毒病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58191, encryptionId=4d3058191e5, topicName=新型冠状病毒病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Jul 29 02:33:02 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292510, encodeId=2b2512925107f, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292882, encodeId=33d8129288256, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610394, encodeId=7f1416103948c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056093, encodeId=67e5205609398, content=<a href='/topic/show?id=4d3058191e5' target=_blank style='color:#2F92EE;'>#新型冠状病毒病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58191, encryptionId=4d3058191e5, topicName=新型冠状病毒病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Jul 29 02:33:02 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292510, encodeId=2b2512925107f, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292882, encodeId=33d8129288256, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610394, encodeId=7f1416103948c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 30 04:33:02 CST 2020, time=2020-03-30, status=1, ipAttribution=)]

相关资讯

JCO:veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后

胰腺导管细胞癌占恶性肿瘤死亡率的第四位,50%的患者诊断时已处于晚期。细胞毒类药物的联合治疗,如亚叶酸、氟尿嘧啶、伊立替康及奥沙利铂、吉西他滨和紫杉醇等药物改善了患者预后,但5年OS率仍低于10%。5

Heart:经导管二尖瓣修复的左心房压力正常患者特征和预后

TMVR时LAP正常与CLD发病率升高相关,而CLD可独立预测1年死亡率升高。

Eur Arch Otorhinolaryngol:中性粒细胞与淋巴细胞比例在先天性突发感觉神经听力损失中的预后价值调查

先天突发性感觉神经性听力损失(ISSNHL)的病因学、治疗和预后到目前仍旧不确定,尽管已经有了充分的调查。

Crit Care:急性肾损伤危重患者给予速尿与预后之间的关系

由此可见,在AKI的重症患者中,应用速尿与改善短期生存率和改善肾功能有关。速尿对UO定义的2-3期AKI患者特别有效。但是,它对SCr定义的2-3期AKI患者和慢性肾脏疾病患者无效。需要在随机对照试验中进一步验证这些结果。

Heart:平均像素强度法预测继发性二尖瓣返流的预后

使用API法进行SMR分级是临床预后的独立预测指标。

Brit J Cancer:PD-L2和PD-L1表达在食管癌患者中预后和临床意义

PD-L2和PD-L1与食管癌患者的不良预后相关,这支持了PD-L2作为食管癌预后生物标志物的作用。